The cytokine and chemokine network in psoriasis

Clinics in Dermatology

Volumn 25, Issue 6, 2007, Pages 568-573

  Nickoloff, Brian J ^a   Xin, Hong ^a   Nestle, Frank O ^b   Qin, Jian Zhong ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CUTANEOUS T CELL ATTRACTING CHEMOKINE; CXCL1 CHEMOKINE; CXCL9 CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 19; INTERLEUKIN 2; INTERLEUKIN 20; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; EPIDERMIS CELL; HUMAN; KERATINOCYTE; LYMPHOCYTIC INFILTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PSORIASIS; T LYMPHOCYTE;

ANIMALS; CHEMOKINES; CYTOKINES; EPIDERMIS; HUMANS; INFLAMMATION; KERATINOCYTES; PSORIASIS;

EID: 36148992962     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2007.08.011     Document Type: Article

References (72)

1. Stern R.S., Nijsten T., Feldman S.R., Margolis D.J., and Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 9 (2004) 136-139
2. Langley R.G., Krueger G.G., and Griffiths C.E. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 64 Suppl 2 (2005) ii18-ii23
3. Hamminga E.A., van der Lely A.J., Neumann H.A., and Thio H.B. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses 67 (2006) 768-773
4. Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B., and Gelfand J.M. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol (2006) 1016
5. Sommer D., Jenisch S., Suchan M., Christophers E., and Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 298 (2006) 321-328
6. Nickoloff B.J., and Nestle F.O. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 113 (2004) 1664-1675
7. Lebwohl M. Psoriasis. Lancet 361 (2003) 1197-1204
8. Esche C., Stellato C., and Beck L.A. Chemokines: key players in innate and adaptive immunity. J Invest Dermatol 125 (2005) 615-628
9. Zlotnik A., and Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 12 (2000) 121-127
10. Gaspari A.A. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 54 (2006) S67-S80
11. Mackay C.R. Chemokines: immunology's high impact factors. Nat Immun 2 (2001) 95-101
12. Robert C., and Kupper T.S. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 341 (1999) 1817-1828
13. Gordon K.B., and Nickoloff B.J. Adhesion molecules and inflammatory cell migration pathways in the skin. In: Bos J.D. (Ed). Skin immune system: cutaneous immunology and clinical immunodermatology (2004), CRC Press, Amsterdam 447-455
14. Ono S.J., Nakamura T., Miyazaki D., Ohbayashi M., Dawson M., and Toda M. Chemokines: roles in leukocyte development, trafficking, and effector function. J Allergy Clin Immunol 111 (2003) 1185-1199
15. Nathan C. Points of control in inflammation. Nature 420 (2002) 846-852
16. Krueger J.G., and Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 64 Suppl 2 (2005) ii30-ii36
17. Bowcock A.M., and Krueger J.G. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 5 (2005) 699-711
18. Nickoloff B.J., Bonish B.K., Marble D.J., et al. Lessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammation. J Invest Dermatol Symp Proc 11 (2006) 16-29
19. Serhan C.N., and Savill J. Resolution of inflammation: the beginning programs the end. Nat Immun 6 (2005) 1191-1197
20. Bergers M., van de Kerkhof P.C., Happle R., and Mier P.D. Membrane-bound phospholipase C activity in normal and psoriatic epidermis. Acta Derm Venereol 70 (1990) 57-59
21. Fisher G.J., Talwar H.S., Baldassare J.J., Henderson P.A., and Voorhees J.J. Increased phospholipase C-catalyzed hydrolysis of phosphatidylinositol-4,5-bisphosphate and 1,2-sn-diacylglycerol content in psoriatic involved compared to uninvolved and normal epidermis. J Invest Dermatol 95 (1990) 428-435
22. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 338 (1998) 436-445
23. Luger T.A., Stadler B.M., Katz S.I., and Oppenheim J.J. Epidermal cell (keratinocyte)-derived thymocyte-activating factor (ETAF). J Immunol 127 (1981) 1493-1498
24. Mosmann T.R., and Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17 (1996) 138-146
25. Mosmann T.R., and Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7 (1989) 145-173
26. Schön M.P., and Boehncke W.H. Psoriasis. N Engl J Med 352 (2005) 1899-1912
27. Nickoloff B.J. The cytokine network in psoriasis. Arch Dermatol 127 (1991) 871-884
28. Nickoloff B.J., Karabin G.D., Barker J.N., et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 138 (1991) 129-140
29. Austin L.M., Ozawa M., Kikuchi T., Walters I.B., and Krueger J.G. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 113 (1999) 752-759
30. Ferenczi K., Burack L., Pope M., Krueger J.G., and Austin L.M. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun 14 (2000) 63-78
31. Schlaak J.F., Buslau M., Jochum W., et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 102 (1994) 145-149
32. Uyemura K., Yamamura M., Fivenson D.F., Modlin R.L., and Nickoloff B.J. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 101 (1993) 701-705
33. Morhenn V.B., Pregerson-Rodan K., Mullen R.H., et al. Use of recombinant interferon gamma administered intramuscularly for the treatment of psoriasis. Arch Dermatol 123 (1987) 1633-1637
34. Funk J., Langeland T., Schrumpf E., and Hanssen L.E. Psoriasis induced by interferon-alpha. Br J Dermatol 125 (1991) 463-465
35. Gottlieb A.B., Chamian F., Masud S., et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 175 (2005) 2721-2729
36. Li H.H., Lin Y.C., Chen P.J., et al. Interleukin-19 upregulates keratinocyte growth factor and is associated with psoriasis. Br J Dermatol 153 (2005) 591-595
37. Piskin G., Sylva-Steenland R.M., Bos J.D., and Teunissen M.B. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 176 (2006) 1908-1915
38. Wei C.C., Chen W.Y., Wang Y.C., et al. Detection of IL-20 and its receptors on psoriatic skin. Clin Immunol 117 (2005) 65-72
39. Wittmann M., Purwar R., Hartmann C., Gutzmer R., and Werfel T. Human keratinocytes respond to interleukin-18: implication for the course of chronic inflammatory skin diseases. J Invest Dermatol 124 (2005) 1225-1233
40. Wolk K., Witte E., Wallace E., et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 36 (2006) 1309-1323
41. Mueller W., and Herrmann B. Cyclosporin A for psoriasis. Engl J Med 301 (1979) 555
42. Ellis C.N., Gorsulowsky D.C., Hamilton T.A., et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 256 (1986) 3110-3116
43. Krueger G.G., Bergstresser P.R., Lowe N.J., Voorhees J.J., and Weinstein G.D. Psoriasis. J Am Acad Dermatol 11 (1984) 937-947
44. Burns M.K., Ellis C.N., Eisen D., et al. Intralesional cyclosporine for psoriasis. Relationship of dose, tissue levels, and efficacy. Arch Dermatol 128 (1992) 786-790
45. Gottlieb A.B., Lebwohl M., Shirin S., et al. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 43 (2000) 595-604
46. Abrams J.R., Kelley S.L., Hayes E., et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 192 (2000) 681-694
47. Krueger J.G. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46 (2002) 1-23
48. Asadullah K., Döcke W.D., Ebeling M., et al. Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol 135 (1999) 187-192
49. Kimball A.B., Kawamura T., Tejura K., et al. Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10. Arch Dermatol 138 (2002) 1341-1346
50. Ghoreschi K., Thomas P., Breit S., et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 9 (2003) 40-46
51. Trepicchio W.L., Ozawa M., Walters I.B., et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 104 (1999) 1527-1537
52. Nash P.T., and Florin T.H. Tumour necrosis factor inhibitors. Med J Aust 183 (2005) 205-208
53. Gordon K.B., Bonish B.K., Patel T., Leonardi C.L., and Nickoloff B.J. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol 153 (2005) 945-953
54. Krüger-Krasagakis S., Galanopoulos V.K., Giannikaki L., Stefanidou M., and Tosca A.D. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis. Br J Dermatol 154 (2006) 460-466
55. Malaviya R., Sun Y., Tan J.K., et al. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J Am Acad Dermatol 55 (2006) 590-597
56. Boyman O., Hefti H.P., Conrad C., Nickoloff B.J., Suter M., and Nestle F.O. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 199 (2004) 731-736
57. Nestle F.O., Conrad C., Tun-Kyi A., et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-{alpha} production. J Exp Med 202 (2005) 135-143
58. Nestle F.O., and Gilliet M. Defining upstream elements of psoriasis pathogenesis: an emerging role for interferon alpha. J Invest Dermatol 125 (2005) xiv-xv
59. Bhushan M., Bleiker T.O., Ballsdon A.E., et al. Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br J Dermatol 146 (2002) 824-831
60. Schön M.P., Krahn T., Schön M., et al. Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat Med 8 (2002) 366-372
61. Toichi E., Torres G., McCormick T.S., et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 177 (2006) 4917-4926
62. Iwakura Y., and Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 116 (2006) 1218-1222
63. Kolls J.K., and Linden A. Interleukin-17 family members and inflammation. Immunity 21 (2004) 467-476
64. Chen Y., Thai P., Zhao Y.H., Ho Y.S., DeSouza M.M., and Wu R. Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J Biol Chem 278 (2003) 17036-17043
65. Albanesi C., Scarponi C., Cavani A., Federici M., Nasorri F., and Girolomoni G. Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma-and interleukin-4-induced activation of human keratinocytes. J Invest Dermatol 115 (2000) 81-87
66. Kanda N., Koike S., and Watanabe S. IL-17 suppresses TNF-alpha-induced CCL27 production through induction of COX-2 in human keratinocytes. J Allergy Clin Immunol 116 (2005) 1144-1150
67. Teunissen M.B., Koomen C.W., de Waal M.R., Wierenga E.A., and Bos J.D. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 111 (1998) 645-649
68. Cataisson C., Pearson A.J., Tsien M.Z., et al. CXCR2 ligands and G-CSF mediate PKCalpha-induced intraepidermal inflammation. J Clin Invest 116 (2006) 2757-2766
69. Paniagua R.T., Sharpe O., Ho P.P., et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 116 (2006) 2633-2642
70. Nickoloff B.J. Keratinocytes regain momentum as instigators of cutaneous inflammation. Trends Mol Med 12 (2006) 102-106
71. Stratis A., Pasparakis M., Rupec R.A., et al. Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J Clin Invest 116 (2006) 2094-2104
72. Wang H., Peters T., Kess D., et al. Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 116 (2006) 2105-2114